title: [Patient's beliefs about oral targeted therapies and impact on drug adherence in lung cancer: A pilot prospective study].
abstract: BACKGROUND
  Oral targeted therapies are a new option for lung cancer treatment. However, patient's belief about these drugs - which may interact with adherence - is poorly known in this setting.
  
  
  METHODS
  Our study is a pilot prospective unicentric study. Inclusion criteria were: to have been diagnosed with a lung cancer; and to be prescribed with an oral targeted therapy in second line or more. The main objective was to assess patient's specific (SB) and general beliefs (GB) about these drugs according to the Beliefs about Medicines Questionnaire (BMQ). The declared adherence was assessed with the Morisky's test. All included patients underwent a semi-structured interview with a psychologist.
  
  
  RESULTS
  Fifthteen patients were included: 12 underwent erlotinib treatment and 3 a crizotinib treatment. The mean score (±standard deviation) at BMQ was 54/85 (±6) overall; 34/50 (±5) for specific belief and 19/35 (±3) for general belief about drugs. During interview, 47% believed in efficacy of targeted oral therapy; 93% reported concerns about their drug; 80% considered that the information given by the physician about the drug was comprehensive; but 40% still required additional information about it. The mean score at Morisky's test was 3/4 (±2) and 53% reported to have forgotten at least once their antineoplastic drug. No correlation was found between belief and adherence.
  
  
  CONCLUSIONS
  Belief about t anti-cancer targeted oral therapy is relatively fair but adherence is moderate in this pilot study. Interview shows the need for additional information about the prescribed drug.
authors.affiliation: Centre de coordination en cancérologie, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France; Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France.
authors.forename: S
authors.initials: S
authors.lastname: Torrecillas
authors.affiliation: Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France.
authors.forename: E
authors.initials: E
authors.lastname: Perrot
authors.affiliation: Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France.
authors.forename: L
authors.initials: L
authors.lastname: Gérinière
authors.affiliation: Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France.
authors.forename: M
authors.initials: M
authors.lastname: Locatelli-Sanchez
authors.affiliation: Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université Lyon I, 69600 Oullins, France.
authors.forename: L
authors.initials: L
authors.lastname: Laffay
authors.affiliation: Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université Lyon I, 69600 Oullins, France.
authors.forename: P-J
authors.initials: PJ
authors.lastname: Souquet
authors.affiliation: Service de pneumologie aiguë spécialisée et cancérologie thoracique, hospices civils de Lyon, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite cedex, France; Faculté de médecine et de maïeutique Lyon Sud Charles-Mérieux, université Lyon I, 69600 Oullins, France. Electronic address: sebastien.couraud@chu-lyon.fr.
authors.forename: S
authors.initials: S
authors.lastname: Couraud
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D000077547:Crizotinib; D003469:Culture; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D008297:Male; D055118:Medication Adherence / Q000523:psychology; D058990:Molecular Targeted Therapy / Q000523:psychology*; D010865:Pilot Projects; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D011795:Surveys and Questionnaires; D016903:Drug Monitoring
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D000069347:Erlotinib Hydrochloride
keywords: Adherence; Belief; Cancer broncho-pulmonaire; Croyance; Inhibiteur des tyrosine-kinases (ITK); Lung cancer; Observance; Tyrosine kinase inhibitors